281 related articles for article (PubMed ID: 33713301)
21. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
Kashima K; Sato N; Sato K; Shimizu H; Mori M
Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
[TBL] [Abstract][Full Text] [Related]
22. Neuroprotection by the pyridoindole stobadine: a minireview.
Stolc S; Vlkolinský R; Pavlásek J
Brain Res Bull; 1997; 42(5):335-40. PubMed ID: 9092873
[TBL] [Abstract][Full Text] [Related]
23. Carboxymethylated tetrahydropyridoindoles as aldose reductase inhibitors: in vitro selectivity study in intact rat erythrocytes in relation to glycolytic pathway.
Juskova M; Snirc V; Gajdosikova A; Gajdosik A; Krizanova L; Stefek M
Gen Physiol Biophys; 2009 Dec; 28(4):325-30. PubMed ID: 20097954
[TBL] [Abstract][Full Text] [Related]
24. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
25. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
26. In vitro studies of potent aldose reductase inhibitors: Synthesis, characterization, biological evaluation and docking analysis of rhodanine-3-hippuric acid derivatives.
Celestina SK; Sundaram K; Ravi S
Bioorg Chem; 2020 Apr; 97():103640. PubMed ID: 32086051
[TBL] [Abstract][Full Text] [Related]
27. Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury.
El Gamal H; Eid AH; Munusamy S
Biomed Res Int; 2017; 2017():5903105. PubMed ID: 28386557
[TBL] [Abstract][Full Text] [Related]
28. Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study.
El-Sayed S; Metwally K; El-Shanawani AA; Abdel-Aziz LM; El-Rashedy AA; Soliman MES; Quattrini L; Coviello V; la Motta C
Bioorg Med Chem Lett; 2017 Oct; 27(20):4760-4764. PubMed ID: 28935265
[TBL] [Abstract][Full Text] [Related]
29. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
[TBL] [Abstract][Full Text] [Related]
30. Standardized extracts of flavonoids increase the viability of PC12 cells treated with hydrogen peroxide: effects on oxidative injury.
Horáková L; Licht A; Sandig G; Jakstadt M; Duracková Z; Grune T
Arch Toxicol; 2003 Jan; 77(1):22-9. PubMed ID: 12491037
[TBL] [Abstract][Full Text] [Related]
31. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
[TBL] [Abstract][Full Text] [Related]
32. IMM-H004, a Novel Coumarin Derivative Compound, Inhibits H
Song XY; Hu JF; Wu DH; Ji HJ; Chen NH
J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3396-3403. PubMed ID: 30243729
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis.
Gleissner CA; Sanders JM; Nadler J; Ley K
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1137-43. PubMed ID: 18451330
[TBL] [Abstract][Full Text] [Related]
34. 6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
Kato A; Kobayashi K; Narukawa K; Minoshima Y; Adachi I; Hirono S; Nash RJ
Bioorg Med Chem Lett; 2010 Oct; 20(19):5630-3. PubMed ID: 20805028
[TBL] [Abstract][Full Text] [Related]
35. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling.
Gu J; Wang JJ; Yan J; Cui CF; Wu WH; Li L; Wang ZS; Yu M; Gao N; Liu L; Ouyang DS
J Ethnopharmacol; 2011 Jan; 133(1):6-13. PubMed ID: 20817083
[TBL] [Abstract][Full Text] [Related]
36. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
[TBL] [Abstract][Full Text] [Related]
37. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
Grewal AS; Bhardwaj S; Pandita D; Lather V; Sekhon BS
Mini Rev Med Chem; 2016; 16(2):120-62. PubMed ID: 26349493
[TBL] [Abstract][Full Text] [Related]
38. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
Inaba M; Terada M; Nishizawa Y; Shioi A; Ishimura E; Otani S; Morii H
Metabolism; 1999 Jul; 48(7):904-9. PubMed ID: 10421234
[TBL] [Abstract][Full Text] [Related]
39. Development of the new group of indole-derived neuroprotective drugs affecting oxidative stress.
Stolc S; Snirc V; Májeková M; Gáspárová Z; Gajdosíková A; Stvrtina S
Cell Mol Neurobiol; 2006; 26(7-8):1495-504. PubMed ID: 16705480
[TBL] [Abstract][Full Text] [Related]
40. Aldose reductase structures: implications for mechanism and inhibition.
El-Kabbani O; Ruiz F; Darmanin C; Chung RP
Cell Mol Life Sci; 2004 Apr; 61(7-8):750-62. PubMed ID: 15095000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
